Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity

What It Covers

Andrew Huberman joins a16z partner Daisy Wolf to map the shift from passive healthcare to active biology management — covering GLP-1 drugs like retatrutide, gray-market peptides including BPC-157 and melanotan, sleep-writing technologies, real-time cortisol sensing, and the trajectory of consumer health over the next five years.

Key Questions Answered

• •GLP-1 trajectory: Nearly one in seven Americans currently takes a GLP-1 drug, with 20% having tried one. Retatrutide, Eli Lilly's next-generation compound, enables up to one-third body weight loss with greater muscle sparing than predecessors. Huberman projects over half of Americans — particularly those from high-obesity communities — will use GLPs within five years, mostly at lower-than-prescribed doses via compounding pharmacies.
• •Peptide risk stratification: Source quality determines safety when using gray-market peptides. Compounding pharmacies offer the highest non-pharmaceutical standard, followed by gray-market research suppliers with purity datasheets (typically 99% pure). Black-market sources — often called "Chinese peptides" — carry unknown contents. BPC-157 shows no recorded human fatalities but poses tumor vascularization risk, making short-term injury use a more defensible application than chronic systemic dosing.
• •Sleep optimization hierarchy: Huberman outlines a near-future sleep stack: cool core body temperature via palm or foot contact rather than cooling entire rooms, use an eye-mask that induces lateral eye movement to trigger sleep onset within six minutes, then apply a 10,000-lux burst upon waking. Growth hormone secretagogues — tesamorelin, ipamorelin, sermorelin, MK-677 — taken 30 minutes before sleep on an empty stomach measurably increase deep sleep and overnight GH release.
• •Cortisol timing as a master lever: A large morning cortisol spike followed by a trough in the late afternoon correlates with better mental health, cancer outcomes, and longevity. Eating starchy carbohydrates in the evening — particularly two to four hours after resistance training — helps lower elevated evening cortisol and significantly improves sleep quality. People on very low-carbohydrate diets frequently report disrupted sleep due to chronically elevated cortisol from insufficient glucose availability.
• •Reading vs. writing biology: Wearables currently read biology — glucose, HRV, sleep stages — but cannot yet write to it. Huberman identifies real-time continuous cortisol monitoring as the next high-value diagnostic frontier. On the writing side, non-invasive neurostimulation via eyes, ears, and superficial facial nerves represents the most accessible near-term pathway to controlling focus, sleep onset, and arousal states without pharmaceuticals or implanted hardware.